Business Context and Reporting Period
Company: Matinas Biopharma Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 26, 2016 (Event Date: July 29, 2016)
Context: The Company announced the closing of a private placement offering of Series A Preferred Stock to accredited investors.
Key Financial Metrics
- Gross Proceeds: $4.4 million from the sale of 880,058 Series A Preferred Shares at $5.00 per share.
- Net Proceeds: Approximately $3.8 million after deducting placement agent fees and estimated offering expenses.
- Placement Agent Fees: $440,029 in cash fees and $132,008.70 in non-accountable expense allowances.
- Warrant Issuance: Warrants issued to the Placement Agent to purchase 88,006 shares of Common Stock at an exercise price of $0.50 per share.
- Dividend Rate: Series A Preferred Shares accrue dividends at 8.0% per year, payable in Common Stock upon conversion.
Material Changes and Transaction Details
The Company entered into definitive subscription agreements and filed a Certificate of Designation for the Series A Preferred Stock. Key terms include:
- Conversion: Shares are convertible into Common Stock at an initial price of $0.50 per share. Automatic conversion occurs upon the earlier of: (i) Company election (deemed 3-year anniversary for dividend calculation), (ii) three years from closing, or (iii) FDA/EMA approval of product candidates MAT2203 or MAT2501.
- Liquidation Preference: Holders receive the Stated Value ($5.00) plus accrued dividends before Common Stock holders.
- Royalty Rights: Holders are entitled to 3% to 4.5% of net sales and 5% to 7.5% of licensing proceeds for MAT2203 and MAT2501. These rights vest in equal thirds over three years or fully upon early conversion.
- Related Party Participation: Certain officers, directors, and affiliates of the Placement Agent purchased shares in this offering.
Outlook, Risks, and Contingencies
- Future Obligations: The Company agreed to a three-year, non-exclusive finder's fee agreement with the Placement Agent for future business combinations, joint ventures, or licensing arrangements, with fees ranging from 2.5% to 5% of consideration.
- Regulatory Status: Securities were issued under Section 4(a)(2) and Rule 506(b) exemptions and are restricted under Rule 144.
- Product Dependence: Automatic conversion and royalty vesting are contingent on the regulatory approval of specific product candidates (MAT2203 and MAT2501).
Investor Verification Checklist
- Verify the full text of the Certificate of Designation of Series A Preferred Stock (Exhibit 3.1).
- Confirm the exact vesting schedule of royalty rights relative to the Initial Closing date.
- Review the Placement Agency Agreement for details on the finder's fee structure for future transactions.
- Assess the dilution impact of the 88,006 warrants issued to the Placement Agent and potential future conversions of Preferred Shares.
- Check for any subsequent filings regarding the final closing of the Offering or additional tranches.